Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Core Insights - Relay Therapeutics is a clinical-stage company focused on developing small molecule precision medicine for cancer and genetic diseases [2] - The company will report its fourth quarter and full year 2025 financial results on February 26, 2026 [1] Company Overview - Relay Therapeutics utilizes its Dynamo® platform, which combines advanced computational and experimental methods to target previously difficult-to-drug proteins [2] - The lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in Phase 3 trials for HR+/HER2- metastatic breast cancer [2] - Zovegalisib is also being studied for PI3Kα-driven vascular anomalies and the company has additional programs targeting NRAS-driven solid tumors and Fabry disease [2]